High-bioavailability Amoxicillin meeting Austrian pharmaceutical standards for infection control.
Essential IV fluids manufactured with precision for Austrian medical facility requirements.
Reliable therapeutic solutions for PE treatment in the European market.
Advanced plastic ampule packaging designed for clinical safety and convenience.
Austria’s pharmaceutical market is one of the most sophisticated in the European Union, characterized by a robust social insurance system (ÖGK) and stringent regulatory oversight by the BASG (Federal Office for Safety in Health Care). As healthcare costs continue to rise, the Austrian government and health insurance providers have increasingly pivoted toward generic medications to maintain high standards of patient care while ensuring fiscal sustainability.
Generic medicines in Austria now account for a significant portion of prescriptions, particularly in off-patent primary care. The "Reimbursable List" (Erstattungskodex) demands not only competitive pricing but also uncompromising stability and proven bioequivalence. As a leading supplier from China, Jiangxi Serum Pharma understands the "Information Gain" required to penetrate this market: it’s not just about the molecule, but the documentation, the purity profiles, and the reliability of the supply chain.
The Austrian generic market is projected to grow by 4.2% annually, driven by patent expirations of key biologics and high-volume small molecules.
"Supply chain resilience is now the #1 priority for Austrian procurement managers after the disruptions of 2022-23."
Established Excellence
Global Partners
Annual Sales (USD)
Verified Suppliers
For nearly a decade, Jiangxi Serum Pharma has stood as a beacon of professional pharmaceutical and nutritional exports in China. Our expertise spans biological products, vaccines, Western medicines, and medical consumables. We don't just export; we bridge the gap between high-scale Chinese manufacturing efficiency and the precise quality requirements of the European pharmaceutical industry.
The traditional "low-cost" perception of Chinese manufacturing has evolved into a "high-tech and scale" reality. For an Austrian pharmaceutical wholesaler or hospital group, partnering with us offers several distinct advantages:
Our capacity to produce millions of units per month ensures that the Austrian market remains shielded from localized drug shortages (Lieferengpässe), which have plagued European markets recently.
We control much of our supply chain, from Active Pharmaceutical Ingredients (API) to finished dosage forms, ensuring transparency and cost-efficiency that is passed directly to our Austrian partners.
All facilities are strictly GMP compliant. We maintain rigorous Quality Assurance (QA) and Quality Control (QC) protocols that align with EMA (European Medicines Agency) expectations.
Serum Pharma continuously monitors cutting-edge market developments to provide "Information Gain" beyond standard trading services. We offer advanced customization in:
Customized pre-formulated mixtures for specific therapeutic requirements, reducing manufacturing steps for local Austrian pharmaceutical compounding.
Enhancing the solubility and stability of APIs through advanced crystal engineering, a critical factor for next-generation generics.
Utilizing high-tech fermentation processes for vitamins, probiotics, and specialized nutritional ingredients with Austrian purity standards.
Beyond traditional Western medicine, the Austrian market shows a strong preference for Plant-Derived and Pure Nutritional Ingredients. Our portfolio covers:
In Austria, where "Organic" and "Natural" are part of the cultural fabric (Bio-Produkte), our nutritional ingredients provide the raw materials necessary for local manufacturers to produce high-end supplements that meet the "Nature to Balance" philosophy.
Exploring the shift in the Austrian cosmetic and pharma industry toward sustainable squalene sources...
Read Full Report →Why this molecule remains essential for Austrian emergency medicine and chronic inflammation management...
Read Full Report →Lilly's latest oral small-molecule GLP-1 drug and its implications for the Austrian weight-loss pharmaceutical sector...
Read Full Report →We work closely with EU-based Qualified Persons (QP) to ensure all dossiers meet the EudraLex requirements. Our manufacturing facilities are GMP-certified, and we provide comprehensive stability data that satisfies BASG’s rigorous safety standards for the Austrian market.
For standard generic medicines, our maritime logistics take approximately 35-45 days. However, for urgent hospital requirements, we utilize temperature-controlled air freight which can reach Austrian logistics hubs within 7-10 days, including customs clearance assistance.
Yes. We offer comprehensive OEM/ODM services, including packaging design that complies with Austrian language requirements (German labeling) and barcode standards (PHARZENT). We ensure all "Gebrauchsinformation" (Package Leaflets) are accurately translated and formatted.
We utilize advanced Phase Change Material (PCM) shippers and real-time GPS/Temperature monitoring (data loggers) to ensure that the cold chain remains unbroken from our factory in China to the final destination in Austria, maintaining the 2°C to 8°C range throughout.
Absolutely. We act as a primary or secondary strategic source, allowing Austrian firms to diversify their supply chains away from over-reliance on a single geographic region, thereby mitigating risks of stock-outs.
Precise dosage thyroid replacement therapy for Austrian patients.
Broad-spectrum penicillin compliant with EU Pharmacopoeia (Ph. Eur.) standards.
Injectable anti-infectives designed for acute clinical care environments.
Reliable treatment for penicillin-sensitive bacterial infections.
Sterile powder for injection, meeting high-volume hospital needs.
Targeted therapy for resistant staph infections in clinical settings.
Sustained-release penicillin injection for systemic infections.
First-generation cephalosporin for outpatient antibiotic care.
